Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Short Interest Down 12.3% in November

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) was the recipient of a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 3,410,000 shares, a decrease of 12.3% from the November 15th total of 3,890,000 shares. Based on an average trading volume of 476,600 shares, the days-to-cover ratio is currently 7.2 days.

Aldeyra Therapeutics Price Performance

Shares of NASDAQ ALDX opened at $4.90 on Monday. Aldeyra Therapeutics has a 1-year low of $2.71 and a 1-year high of $6.55. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18. The company has a 50-day moving average of $5.15 and a two-hundred day moving average of $4.74.

Aldeyra Therapeutics (NASDAQ:ALDX) last released its earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.25). On average, equities research analysts expect that Aldeyra Therapeutics will post -0.92 earnings per share for the current year.

Institutional Investors Weigh In On Aldeyra Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of ALDX. Perceptive Advisors LLC boosted its position in shares of Aldeyra Therapeutics by 7.9% in the 2nd quarter. Perceptive Advisors LLC now owns 9,275,851 shares of the biotechnology company’s stock worth $30,703,000 after purchasing an additional 682,265 shares during the last quarter. State Street Corp boosted its position in shares of Aldeyra Therapeutics by 1.7% during the third quarter. State Street Corp now owns 973,908 shares of the biotechnology company’s stock worth $5,249,000 after purchasing an additional 16,188 shares in the last quarter. Federated Hermes Inc. acquired a new stake in Aldeyra Therapeutics during the 2nd quarter worth $1,758,000. Jacobs Levy Equity Management Inc. grew its stake in Aldeyra Therapeutics by 163.4% in the third quarter. Jacobs Levy Equity Management Inc. now owns 476,949 shares of the biotechnology company’s stock valued at $2,571,000 after acquiring an additional 295,864 shares during the period. Finally, PFG Investments LLC bought a new stake in shares of Aldeyra Therapeutics in the second quarter worth about $1,312,000. 59.71% of the stock is owned by institutional investors.

About Aldeyra Therapeutics

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.